Figure 3: Serum ADAMTS13 antibody by Western blotting.
From: CD4+CD25+ T Cells in primary malignant hypertension related kidney injury
ADAMTS13 antibody (positive %) accounted for 81% of the primary MHTN related kidney injury patients. Controls were negative. Lane M: Marker; lane 1: Controls; lane 2: Controls; lane 3: primary MHTN related kidney injury patients (Mild lesion); lane 4: primary MHTN related kidney injury patients (Moderate lesion); lane 5: primary MHTN related kidney injury patients(Marked lesion).
